District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
NCT03728985
Recruiting
Prospective, non-randomized, , multicenter study with two independent arms: Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. Up to 65 additional subjects may be implanted in Continued Access Phase under the Primary Study Arm only Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Minimum: 122 implanted subjects. Maximum: 202 implanted subjects with up to 65 additional subjects implanted... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
01/18/2024
Locations: MedStar Health Research Institute - MedStar Washington Hospital, Washington, District of Columbia
Conditions: Thoracoabdominal Aortic Aneurysm
Register for Updates
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
NCT04064827
Recruiting
The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal Dialysis (PD) or Hemodialysis (HD). The 24-week study is divided into two 12-week dosing periods (Dosing Period 1 followed by Dosing Period 2).
Gender:
All
Ages:
Between 0 years and 9 years
Trial Updated:
01/17/2024
Locations: Children's National Medical Center /ID# 225991, Washington, District of Columbia
Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Register for Updates
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
NCT05715229
Recruiting
This clinical trial plans to assess to what extent the on-treatment circulating tumor DNA (ctDNA) can predict the subset of patients with NSCLC who will respond to immunotherapy treatment only and which patients will need both immunotherapy and chemotherapy modalities for their treatment regimen.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
NCT05107128
Recruiting
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance and functioning in participants with HD.
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
01/12/2024
Locations: Sage Investigational Site, Washington, District of Columbia
Conditions: Huntington's Disease
Register for Updates
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
NCT02912949
Recruiting
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
Register for Updates
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
NCT02089217
Recruiting
Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical ma... Read More
Gender:
All
Ages:
Between 35 years and 100 years
Trial Updated:
01/12/2024
Locations: Washington Hospital Center/Medstar, Washington, District of Columbia
Conditions: Carotid Stenosis
Register for Updates
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
NCT04401436
Recruiting
Background: COVID-19 is an acute respiratory syndrome. One symptom of COVID-19 is a reduction in the number of cells called lymphocytes in the blood. Lymphocytes are a type of white blood cell that fights infections. With fewer lymphocytes, the body cannot effectively fight back against SARS CoV-2, the virus that causes COVID-19. Researchers want to better understand how SARS-CoV-2 affects these blood cells. This information may give them ideas for new treatments. Objective: To learn more abo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Coronavirus Disease 2019
Register for Updates
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT05233397
Recruiting
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
01/10/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
Register for Updates
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
NCT03586297
Recruiting
The probability of pCR in TNBC patients receiving standard of care neoadjuvant chemotherapy treatment is associated with the dominance of specific intestinal and intratumoral microbiota that promote anti-tumor immunosurveillance.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/08/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Triple Negative Breast Cancer
Register for Updates
PVB vs Ketamine/Lidocaine in Rib Fracture Patients
NCT04413799
Recruiting
Rib fractures are a common admission to the trauma service. The mainstay of treatment is pain control to improve respiratory effort in order to offset the risk of pneumonia and mechanical ventilation. In addition to standard pain control modalities, the investigator's institution utilizes paravertebral blocks as well as lidocaine and ketamine infusions for pain control. The current standard of care for pain control is to begin with acetaminophen, ibuprofen or celecoxib and opioids with the addit... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/05/2024
Locations: The George Washington University Hospital, Washington, District of Columbia
Conditions: Rib Fractures, Rib Trauma, Rib Fracture Multiple, Pain, Acute
Register for Updates
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
NCT04661137
Recruiting
This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma patients with documented disease progression or refractory disease while on current treatment with any carfilzomib-containing regimen (arm 1), any pomalidomide-containing regimen (arm 2) or any daratumumab-containing regimen (exploratory arm) will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Multiple Myeloma
Register for Updates
Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention
NCT00733590
Recruiting
The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pul... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
01/04/2024
Locations: Washington Hospital Center, Washington, District of Columbia
Conditions: Heart Failure, Congestive, Death, Sudden, Cardiac, Arrhythmia, Cardiomyopathies
Register for Updates